Arkema

Asian Overcapacity And Regulatory Hurdles Will Erode Profitability

AnalystLowTarget

Not Invested

Community Contributor

Published

26 Jun 25

n/a

AnalystLowTarget's Fair Value

n/a

-33.1%

-2.5%

-33.1%

-2.5%

You can edit this narrative until Jun 26 10:09 PM. Then, changes will post as Updates.

Author's Valuation

€569.1% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

€56

9.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

2.19%

Chemicals revenue growth rate

0.62%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.90%

Calculation

€385.58m

Earnings '28

14.34x

PE Ratio '28

€5.53b

Market Cap '28

€5.53b

Market Cap '28

78.09m

No. shares '28

€70.82

Share Price '28

€70.82 Share Price '28

Discounted to 2025 @ 8.18% p.a.

€55.93

Fair Value '25